Improving antimicrobial stewardship with penicillin allergy testing: a review of current practices and unmet needs

Author:

Mabilat Claude1,Gros Marie-Françoise1,Van Belkum Alex2,Trubiano Jason A3,Blumenthal Kimberly G45ORCID,Romano Antonino6,Timbrook Tristan T7ORCID

Affiliation:

1. bioMérieux, Medical Affairs , 100 Rue Louis Pasteur, F-69280 Marcy l'Etoile , France

2. bioMérieux, Open Innovation and Partnerships , 3 Route du Port Michaud, 38390 La Balme Les Grottes , France

3. Department of Infectious Diseases, Centre for Antibiotic Allergy and Research , Austin Health, 145 Studley Road, Heidelberg, Victoria, 3084 Australia

4. Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital , Boston, MA , USA

5. Harvard Medical School , Boston, MA , USA

6. Oasi Research Institute-IRCCS, Allergy Unit , Troina , Italy

7. bioMérieux, BioFire Diagnostics, Global Medical Affairs , 515 Colorow Drive, Salt Lake City, UT 84108 , USA

Abstract

Abstract Penicillin allergy, the most frequently reported drug allergy, has been associated with suboptimal antibiotic therapy, increased antimicrobial resistance, increased rates of Clostridioides difficile colonization and infection, as well as extended hospital length of stay and increased cost. Although up to 10% of all patients may report penicillin allergy, most penicillin allergies are not confirmed. As such, most patients with a penicillin allergy can still safely use penicillin and related drugs following a more precise assessment. Herein, we review the current practices and unmet needs in penicillin allergy testing. The diagnostic algorithm is mostly based on a clinical history assessment followed by in vivo testing, i.e. skin test and/or drug challenge. As these tests are labour and resource intensive, there is increased interest in point-of-care penicillin allergy de-labelling solutions incorporated into Antimicrobial Stewardship Programmes including digital assessment tools. These can be locally parameterized on the basis of characteristics of target populations, incidence of specific allergies and local antibiotic usage to perform clinical risk stratification. Safely ruling out any residual risk remains essential and in vivo drug challenge and/or skin testing should be systematically encouraged. Gradual understanding and convergence of the risk stratification of the clinical presentation of penicillin allergy is enabling a wider implementation of this essential aspect of antimicrobial stewardship through digitalized decision tools and in vivo testing. More research is needed to deliver point of care in vitro diagnostic tools to democratize this de-labelling practice, which would be highly beneficial to patient care. This progress, together with better education of patients and clinicians about the availability, efficacy and safety of penicillin allergy testing, will increase the dissemination of penicillin allergy assessment as an important component of Antimicrobial Stewardship Programmes.

Funder

National Health and Medical Research Council

National Institutes of Health

American Academy of Allergy Asthma and Immunology

Publisher

Oxford University Press (OUP)

Subject

Microbiology (medical),Infectious Diseases,Immunology and Allergy,Microbiology,Immunology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3